233 related articles for article (PubMed ID: 33177340)
1. Alterations in Ki67 Labeling Following Treatment of Poorly Differentiated Neuroendocrine Carcinomas: A Potential Diagnostic Pitfall.
Vyas M; Tang LH; Rekhtman N; Klimstra DS
Am J Surg Pathol; 2021 Jan; 45(1):25-34. PubMed ID: 33177340
[TBL] [Abstract][Full Text] [Related]
2. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
4. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.
Tang LH; Untch BR; Reidy DL; O'Reilly E; Dhall D; Jih L; Basturk O; Allen PJ; Klimstra DS
Clin Cancer Res; 2016 Feb; 22(4):1011-7. PubMed ID: 26482044
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
6. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
[TBL] [Abstract][Full Text] [Related]
7. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
[TBL] [Abstract][Full Text] [Related]
8. Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: a comparative cytohistological study of 53 cases.
Carlinfante G; Baccarini P; Berretti D; Cassetti T; Cavina M; Conigliaro R; De Pellegrin A; Di Tommaso L; Fabbri C; Fornelli A; Frasoldati A; Gardini G; Losi L; Maccio L; Manta R; Pagano N; Sassatelli R; Serra S; Camellini L
Virchows Arch; 2014 Jul; 465(1):49-55. PubMed ID: 24807732
[TBL] [Abstract][Full Text] [Related]
9. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification.
Yang Z; Tang LH; Klimstra DS
Am J Surg Pathol; 2011 Jun; 35(6):853-60. PubMed ID: 21566513
[TBL] [Abstract][Full Text] [Related]
10. [Tissue heterogeneity contributes to suboptimal precision of WHO 2010 scoring criteria for Ki67 labeling index in a subset of neuroendocrine neoplasms of the pancreas].
Liszka Ł
Pol J Pathol; 2016; 67(4):318-331. PubMed ID: 28547959
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological Profiling of Lung Carcinoids with a Ki67 Index > 20.
Kasajima A; Konukiewitz B; Oka N; Suzuki H; Sakurada A; Okada Y; Kameya T; Ishikawa Y; Sasano H; Weichert W; Klöppel G
Neuroendocrinology; 2019; 108(2):109-120. PubMed ID: 30485860
[TBL] [Abstract][Full Text] [Related]
12. NET G3 vs NEC: p53 and Rb1 Immunolabeling in High-grade Gastrointestinal Neuroendocrine Neoplasms - Is It Enough for the Differential Diagnosis?
Dinu A; Aschie M; Cozaru GC; Mitroi AF; Grasa CN; Iordache IE; Deacu M; Orasanu CI; Nicolau AA; Baltatescu GI
J Gastrointestin Liver Dis; 2023 Jun; 32(2):162-169. PubMed ID: 37345605
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine Neoplasms of the Larynx: A Clinicopathologic Analysis of 27 Neuroendocrine Tumors and Neuroendocrine Carcinomas.
Bal M; Sharma A; Rane SU; Mittal N; Chaukar D; Prabhash K; Patil A
Head Neck Pathol; 2022 Jun; 16(2):375-387. PubMed ID: 34401980
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications.
Klöppel G
Visc Med; 2017 Oct; 33(5):324-330. PubMed ID: 29177160
[TBL] [Abstract][Full Text] [Related]
15. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
[TBL] [Abstract][Full Text] [Related]
16. World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution.
Yang M; Zeng L; Ke NW; Tan CL; Tian BL; Liu XB; Xiang B; Zhang Y
BMC Cancer; 2020 Sep; 20(1):906. PubMed ID: 32962649
[TBL] [Abstract][Full Text] [Related]
17. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.
Rindi G; Mete O; Uccella S; Basturk O; La Rosa S; Brosens LAA; Ezzat S; de Herder WW; Klimstra DS; Papotti M; Asa SL
Endocr Pathol; 2022 Mar; 33(1):115-154. PubMed ID: 35294740
[TBL] [Abstract][Full Text] [Related]
18. Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites.
Uccella S; La Rosa S; Metovic J; Marchiori D; Scoazec JY; Volante M; Mete O; Papotti M
Endocr Pathol; 2021 Mar; 32(1):192-210. PubMed ID: 33433884
[TBL] [Abstract][Full Text] [Related]
19. An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features.
Kasajima A; Konukiewitz B; Schlitter AM; Weichert W; Klöppel G
Virchows Arch; 2022 Feb; 480(2):359-368. PubMed ID: 34499237
[TBL] [Abstract][Full Text] [Related]
20. APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis.
Feng C; Zheng Q; Yang Y; Xu M; Lian Y; Huang J; Jiang Y
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):599-605. PubMed ID: 30095460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]